Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Guobang PharmaSHSE:605507 +0.06%88 OCF Margin % is 12.70% as of Mar. 2026, which is 9% above its 10-year median of 11.60. GuruFocus rates SHSE:605507 with a GF Score™ of 88/100 and a GF Value™ of ¥16.00 (Fairly Valued). The stock has 4 warning signs investors should review. Among 964 Drug Manufacturers companies, Guobang Pharma ranks better than 73.24% on this metric.
The historical rank and industry rank for Guobang Pharma's OCF Margin % or its related term are showing as below:
SHSE:605507'
s OCF Margin % Range Over the Past 10 Years
Min: -3.91 Med: 11.6 Max: 18.25
Current: 18.12
During the past 9 years, the highest OCF Margin % of Guobang Pharma was 18.25%. The lowest was -3.91%. And the median was 11.60%.
SHSE:605507's OCF Margin % is ranked better than 73.24% of 964
companies
in the Drug Manufacturers industry
Industry Median: 10.06
vs SHSE:605507: 18.12
Guobang Pharma OCF Margin % Related Terms
Guobang Pharma OCF Margin % Historical Data
* Premium members only.
The historical data trend for Guobang Pharma's OCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Guobang Pharma's OCF Margin %, along with its competitors' market caps and OCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Guobang Pharma OCF Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Guobang Pharma's OCF Margin % distribution charts can be found below:
* The bar in red indicates where Guobang Pharma's OCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Guobang Pharma (SHSE:605507) has a OCF Margin % of 12.70% as of Mar. 2026. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Guobang Pharma and its competitors. This is near median its historical median of 11.60. According to the industry distribution chart, Guobang Pharma ranks #258 out of 964 companies in the Drug Manufacturers industry, placing it in the top 26.8%.
Is Guobang Pharma's OCF Margin % too high?
Guobang Pharma's current OCF Margin % of 12.70% is near median its 10-year median of 11.60. The Drug Manufacturers industry median OCF Margin % is 10.06. Guobang Pharma's value of 12.70% is 26.2% above this industry median. Based on the distribution chart, Guobang Pharma ranks #258 out of 964 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Guobang Pharma has a GF Score™ of 88/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Guobang Pharma's OCF Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Guobang Pharma ranks #258 out of 964 companies for OCF Margin %. This puts Guobang Pharma in the upper half of its industry. The industry median OCF Margin % is 10.06. Guobang Pharma's value of 12.70% is 26.2% above this benchmark. While the company's 10-year median is 11.60 vs. the industry median of 10.06, Guobang Pharma has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Drug Manufacturers company?
The median OCF Margin % among Drug Manufacturers companies is 10.06, based on 964 companies in the industry. Companies in the top quartile (top 25%) have a OCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Guobang Pharma's current OCF Margin % of 12.70% is 26.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Guobang Pharma and its competitors. For the Drug Manufacturers industry, the median OCF Margin % is 10.06 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Guobang Pharma's current OCF Margin % is 12.70%, which is near median its own 10-year median of 11.60. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Guobang Pharma stock overvalued right now?
Based on GuruFocus' analysis, Guobang Pharma (SHSE:605507) is currently considered Fairly Valued. The stock's GF Value™ is ¥16.00, compared to a current price of ¥16.30 — trading 1.9% above its estimated fair value. The current OCF Margin % is 12.70%, which is near median its 10-year median of 11.60 and 26.2% above the Drug Manufacturers industry median of 10.06. Guobang Pharma's overall GF Score™ is 88/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Guobang Pharma (SHSE:605507), the current OCF Margin % is 12.70% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Guobang Pharma (SHSE:605507) Overvalued in 2026?
Based on GuruFocus' analysis, Guobang Pharma stock appears to be overvalued.
The current stock price of ¥16.30 is trading 1.9% above its estimated GF Value™ of ¥16.00.
GuruFocus considers Guobang Pharma to be Fairly Valued.
Key valuation signals for SHSE:605507:
OCF Margin %: 12.70% (near median its 10-year median of 11.60)
GF Value™: ¥16.00 vs. price of ¥16.30 (1.9% above fair value)
Industry Position: 26.2% above the Drug Manufacturers median (#258 of 964)
No single metric tells the full story. See the SHSE:605507 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Guobang Pharma Ltd is engaged in the research and development, production and sales of related products in the field of medicine and animal health products.
88GF Score
Get the complete analysis for SHSE:605507
OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:605507 has been successfully added to your 
